LIXT Stock: Overview, Analysis, & Key Investor Considerations
Lixte Biotechnology Holdings Inc. (LIXT Stock) creates and employs enzyme biomarkers linked to diseases and then creates chemicals to attack those identified targets. LIXTE is a drug development business that has created LB-100. The compound is a novel, proprietary, first-in-class protein phosphatase inhibitor. LB-100 has the potential to be widely employed as an anti-cancer agent. The inhibitor can be used alone or in combination with established anti-cancer therapy. For example, cytotoxic medicines, radiation, and immune checkpoint blockers.
LIXTE Biotechnology Holdings, Inc. focuses on developing medications that will lead to more effective therapies for many types of cancer and other significant chronic diseases. Defects in the switches that turn on and off the metabolic processes in cells are a primary cause of cancer. Over the last 30 years, most cancer research has concentrated on the “on” switches. This is because the “off” switches, particularly the master “off” switch protein phosphatase (PP2A), were thought to produce unbearable damage in patients.
The company continues to demonstrate in clinical trials that their innovative PP2A inhibitor LB-100, is well tolerated in cancer patients at levels associated with anti-cancer activity. Their novel strategy promotes cancer cells that have been weakened by chemo or other cancer therapies to multiply. This results in more effective destruction and expulsion of those cells from the body. LIXTE collaborates with renowned medical institutions and academic research institutions to further the clinical development of its products. The LB-100 molecule has no known competitors at this stage of development. The inhibitor is now being investigated in three ongoing clinical studies, with more planned.
LIXTE Biotechnology Holdings (LIXT Stock) – Overview
Lixte Biotechnology Holdings, Inc. is a drug development company. The company was founded in 2005, by John S. Kovach and Robert B. Royds. Lixte is headquartered in Pasadena, California. The company employs biomarker technologies to identify enzyme targets before developing novel compounds to attack those targets. To this end, Lixte’s product pipeline is primarily focused on protein phosphatase inhibitors. These are used alone or in combination with cytotoxic medications, x-rays, and immunological checkpoint blockers. The company has two major therapeutic categories in various stages of pre-clinical and clinical research. These have the potential to treat not only cancer but also other debilitating and life-threatening diseases:
- LB-100 series – consists of novel structures that may be useful in the treatment of cancers and vascular and metabolic diseases.
- LB-200 series – is used to treat chronic hereditary diseases such as Gaucher’s disease, as well as cancer and neurodegenerative diseases.
LIXTE Biotechnology Holdings, Inc. (LIXT Stock) – Investor Relations
LIXTE stock trades on the Nasdaq Exchange using the LIXT Stock ticker symbol. The company’s online portal provides essential information to investors and shareholders.
- LIXTE Inc. Corporate Headquarters
LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd., Suite 180
Pasadena, CA 91101, General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
- LIXTE Inc. Corporate WebSite – lixte.com
- Investor Relations – ir.lixte.com
- LIXT Stock News & Events – ir.lixte.com/press-releases
- LIXT Stock Financial & SEC Reports – ir.lixte.com/sec-filings
LIXTE Biotechnology Inc. (LIXT Stock) Sec Filings
LIXTE, Inc. is primarily in the business of medicinal chemicals & clinical research. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details and a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Lixte Biotechnology Holdings, Inc.
LIXT Stock In the News
LIXTE Biotechnology appoints Bas Van Der Baan to the Board of Directors (June 2022)
Lixte Biotechnology is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company has appointed Bas van der Baan to its Board of Directors as an independent director.
“We are very pleased to welcome Mr. van der Baan to our Board of Directors. Mr. van der Baan has over 20 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He has extensive know-how in the journey from clinical development to reimbursement and commercialization. Moreover, establishing partnerships with the pharmaceutical industry, academic collaborators, distributors, insurance companies, and governments to launch new oncology products. Lixte is now in the clinical phase of development of LB-100, its first-in-class protein phosphatase 2A (PP2A) inhibitor. Our goal is to demonstrate the potential of this novel anti-cancer compound as a major new addition to chemotherapy and immunotherapy regimens. Mr. van der Baan will bring substantial experience and expertise in the commercialization of new modalities in the oncology market to our Board of Directors as we continue the clinical development of LB-100.” (Source: Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte)
Lixte Biotechnology Appoints Prof. Rene Bernards to the Board of Directors (June 2022)
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing and commercializing cancer therapies. The company has appointed Professor René Bernards to its Board of Directors to serve as an independent director.
“We are very pleased to welcome Professor Bernards to our Board of Directors and we look forward to his insight and guidance, as well as benefiting from his extensive experience in the development of effective anti-cancer drugs from their earliest stages through clinical use. Professor Bernards is a leader in the field of molecular carcinogenesis, working at the Netherlands Cancer Institute in Amsterdam. His research focuses on identifying effective new drug combinations, new drug targets, and mechanisms of resistance to anti-cancer drugs. He has also co-founded four biotechnology companies to bring his scientific discoveries to clinical oncology practice. Professor Bernards has received many awards recognizing his excellence in cancer research. He is a member of the Royal Netherlands Academy of Sciences, an International Honorary Member of the American Academy of Arts and Sciences, and an International member of the National Academy of Sciences (USA).” (Source: Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte)
LIXTE Biotechnology Closes $5.8 Million Registered Direct Offering (April 2022)
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT Stock Ticker), announced that it has closed a registered direct offering of $5.8 million of common stock with certain institutional and accredited investors. The company issued a total of 2,900,000 shares of common stock for $2.00 a share. The offering was co-placed by WestPark Capital, Inc. and WallachBeth Capital, LLC.
The gross proceeds to LIXTE from this offering were $5.8 million. This is before deducting the placement agents’ fees and charges, as well as other offering expenses payable. The net proceeds of the sale will be used for working capital and other business costs. The proceeds will further the ongoing clinical development of the Company’s main chemical, LB-100. LIXTE offered the shares of common stock in accordance with a “shelf” registration statement, Form S-3 (File No. 333-252430). This form was previously filed with the Securities and Exchange Commission on January 26, 2021. It was declared effective by the SEC on February 5, 2021.
Up Next: What is Mitbbs stock?
The MITBBS Stock traces back to 1997. Chinese students studying at the Massachusetts Institute of Technology created a bulletin board system (BBS) known as bbs.mit.edu. In 2002, the Chinese government blocked access to the entire mit.edu domain in Mainland China. A bulletin board system can also be called a computer bulletin board service (CBBS). It is a computer server running software that allows users to connect to the system using a terminal program. Once logged in, the user can perform functions such as uploading and downloading software and data, reading news and bulletins, and exchanging messages with other users through forums, public message boards, and direct chatting.
The MITBBS Stock forum, located at bbs.mit.edu, was started in 1997 by Chinese students studying at the Massachusetts Institute of Technology. Five years later, the Chinese authorities barred access to the whole mit.edu domain in Mainland China. Some assume that the main motive was to prevent domestic users from seeing the forum’s uncensored political debates. There were around 300 topic groupings by 2022. The website claimed to have hundreds of thousands of registered members, the majority of whom were Overseas Chinese, and that 51% of their internet traffic came from within the United States.